Excited to share Seurat v6 and scSLIDE!
Single-cell studies usually compare cells, but scSLIDE lets us compare *samples*. Instead of forcing patients into case/control groups, we can model sample-level variation.
Paper: https://t.co/EWcR8u0pPJ
Software: https://t.co/a9UNElq1ri
Multicohort analysis of >540,000 adults with obesity shows a dose–response between BMI and severe infections, with class III obesity nearly tripling infection-related hospitalization and death and an estimated ~1 in 10 infection deaths worldwide attributable to obesity.
https://t.co/eotn0No8n0
Up front & free to read in our July issue #editorspicks: a review by Roy Taylor based on his Claude Bernard Lecture at #EASD2024, Aetiology of type 2 diabetes: an experimental medicine odyssey https://t.co/MdUJ6Yx1hy
📢Coming Soon!
#ANRFIndia – Convergence Research Centres of Excellence (CoE)!
A new era of interdisciplinary research to bring together the depth of core sciences with contextual insight of #socialsciences & #humanities.
🔗https://t.co/nEPnArfg6q
Original Article
Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study
Holmer et al.
#LiverX
https://t.co/nYo6Fb5G59
Original Article
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction–associated steatotic liver diseases: Target trial emulation using real-world data
Ng et al.
#LiverX
https://t.co/o5SRqa2pfh
This is Demis Hassabis.
He’s Google's DeepMind CEO, who’s studied AI for 30+ years.
In his new interview with 60 Minutes, he revealed mind-blowing facts about health & AI that 99% of people wouldn’t know.
Here are my top 8 takeaways: 🧵
(No. 6 will shock you)
Thrilled to share our global consensus recommendations for MASLD/MASH! A comprehensive effort to unify guidelines, improve care, and reduce confusion in managing these metabolic liver diseases. I'd like to extend a heartfelt thank you to @ZobairYounossi@ShiraZelbe31142 and @JVLazarus for their exceptional leadership in this collaborative effort. #MASLD #MASH
https://t.co/W9pzjoh2cf
The @TheLancetEndo Commission's new definitions:
➡️Preclinical obesity is a physical phenotype and a condition of excess body fat that is associated with no ongoing illness.
➡️Clinical obesity is a chronic disease characterized by signs and symptoms of organ dysfunction and/or reduced ability to conduct daily activities.
https://t.co/5dh1kNeVW3
Just out in Cell: the Asian Immune Diversity Atlas (AIDA) is a 5-nation single-cell blood atlas. We show that humans are remarkably diverse in gene expression and cell phenotype, with disease implications #healthcaredisparities#PrecisionMedicine [https://t.co/Rz3ENKb1vm]. [1/14]
There are different clusters of people with #MASLD, partially explaining the heterogeneity in pathophysiology and clinical outcomes.
https://t.co/MIWvrKMXB0